Market Research Logo

Large Volume Wearable Injectors Market (3rd Edition), 2017-2027

Large Volume Wearable Injectors Market (3rd Edition), 2017-2027

Drug delivery systems optimized to provide flexibility in dosing regimen, reduce the number of hospital visits, decrease dependence on healthcare professionals and enhance adherence to the therapeutic regimen have become the preferred choice of drug administration. The large scale adoption of prefilled syringes, the first ready-to-use injection device to be marketed, demonstrated the growing interest in the concept of such convenient drug delivery systems. In addition, several pen-injectors and autoinjectors have witnessed an impressive growth in the recent past. However, these hand-held devices are only capable of administering drugs with dosing volume close to 1 ml. With over 900 biologics being developed (most of these are highly viscous and are required to be delivered in volumes greater than 1 ml), there is a growing demand for self-administration devices than can overcome this unmet need.

Large volume wearable injectors, an advanced version of the existing self-injection devices, are expected to gather interest from a wide customer base. In fact, there are a number of such injectors commercially available for delivery of insulin. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, it is worth highlighting that till date only one large volume wearable injector (SmartDose Electronic Wearable Injector) has been approved for administration of a non-insulin biologic. Despite the uncertainties related to the device development and approval, many companies are investing their time, money and resources to develop these novel devices. In addition to the publically known programs, pharma companies have many undisclosed programs that are likely to provide the necessary growth impetus in the long term.

It is worth noting that the VC community has demonstrated significant interest in funding projects related to such wearable injectors. These investments are expected to drive further innovation and lead to the introduction of novel device candidates in the industry. Quite recently, in January 2017, scPharmaceuticals closed a series B investment round worth USD 45.6 million. The company intends to use the funding to bring Furoscix and the sc2Wear Infusor to the market in the US. Earlier, in July 2016, SteadyMed Therapeutics raised USD 32 million in a private placement round financed by Deerfield Capital Management, Federated Investors and OrbiMed. In September 2015, CeQur completed a USD 100 million Venture (Series C) financing round, which was led by Woodford Investment Management, Arthurian Life Sciences, Endeavour Vision, VI Partners and Schroders.

Several partnerships have also been inked in this domain in the last few years. Most of these are focused on the development / commercialization of a variety of wearable injectors. Such partnerships are important for technological integration, supply of devices and also facilitate the conduct of clinical trials related to drug-device combination products. We believe that the device developers will continue to strive to introduce unique and user-friendly features into their proprietary range of devices. The upgradation of existing devices to more competent / next generation devices will serve as a key driver of immediate near-term growth.

SCOPE OF THE REPORT
The “Large Volume Wearable Injectors Market (3rd Edition), 2017-2027” report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years. With the increasing incidence of chronic and lifestyle-related diseases across the globe, the demand for efficient drug delivery systems is growing at a rapid pace. In order to simplify the process of drug delivery, eliminate costs and reduce the incidence of needlestick injuries, the pharmaceutical industry has shifted its focus towards the development of self-injection devices for parenteral drugs / therapies. This report specifically lays emphasis on the emergence of such patient-centric, convenient, cost-effective and user-friendly wearable injectors that are capable of administering large volumes of a drug subcutaneously in a home-care setting.

It is worth noting that the concept behind such injectors is being widely employed for the delivery of insulin. Over 15 such unique series of injectors (excluding variants) have already entered the market. On the other hand, there is only one large volume wearable injector (mentioned above) approved for the administration of a non-insulin biologic in the US. However, with a variety of biologics under investigation, we believe that device developers have a significant opportunity waiting to be tapped. The field is likely to pick up momentum in the next few years. In fact, an increase in the partnerships and investment activities demonstrate that the market is geared towards significant growth in the mid to long term.

One of the key objectives outlined for the study was to evaluate the future potential of the ongoing development programs of both big and small firms. Amongst other elements, the report elaborates on the following areas:

An overview of the current market landscape in terms of the key players involved, development status of pipeline products (marketed / under development), type of dose (bolus / continuous / both), usability (disposable / reusable) and key indications.

Detailed profiles of large volume wearable devices that are being developed for the delivery of biologics (including insulin), highlighting their key features, current status of development, recent developments and associated collaborations.

An exhaustive review of over 300 biologics, which are potential candidates for delivery using large volume wearable injectors. The molecules / therapies have been categorized into most-likely, likely and less-likely candidates for administration using large volume wearable injectors. This categorization is based on various parameters including recommended volume, route of administration, frequency of the dose, standard / weight based dose and the chronicity of target indication.

Comprehensive case studies on drugs that are being evaluated for delivery via large volume wearable injectors, highlighting their specifications, mechanisms of action, current status of development, sales, respective dosages and any other recent developments.

An illustrative grid representation of the devices based on the category of device (insulin / non-insulin biologic), type of dose and type of device (infusion pump / patch pump). In addition, the report includes an insightful 2 X 2 matrix analysis, highlighting the positioning of the devices based on product competitiveness and supplier power.

A discussion on the key drivers and challenges, in terms of the strengths, weaknesses, opportunities and threats (SWOT), which are likely to impact the future growth of this upcoming area.

The study provides a detailed market forecast and opportunity analysis for the period between 2017 and 2027. The research, analysis and insights presented in this report include potential sales of the drug-device combinations that are being evaluated and are anticipated to enter the market in the next few years. To add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios. It is worth noting that, although the market of insulin delivery devices is relatively more mature, we have included a high-level opportunity analysis on the large volume wearable injectors being developed for delivery of insulin as well.

Our opinions and insights presented in this study were influenced by discussions conducted with several experts in this area. Specifically, we solicited the opinions of senior representatives including Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. There are over 50 different large volume wearable injectors (including variants) that are either commercialized or are under development. Of these, around 60% are for delivery of insulin and the rest are for delivery of other biologics. Of the devices being developed for delivery of non-insulin biologics, SmartDose Electronic Wearable Injector (by West Pharmaceutical Services) has already received approval by the USFDA for delivery of Repatha.

2. There are several other known references of drug-device combinations that are being evaluated in clinical studies; examples include SteadyMed Therapeutics’ PatchPump (with Treprostinil and Ketorolac), NeuroDerm’s CRONO ND (with NDO612 and NDO712), Roche’s Single-use injection device (with Herceptin) and scPharmaceuticals’s scWear Infusor (with Ceftriaxone and Furosemide).

3. The commercially available insulin-based large volume wearable injectors can accommodate volumes of up to 5 ml. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, with improved design, several devices with capacity of holding up to 20 ml drug are being developed for delivery of biologics. In fact, over 50% of the devices that we identified for administration of non-insulin biologics have the capability of carrying 5-20 ml drug while 16% of these devices can hold over 20 ml drug.

4. Our analysis suggests that close to 100 biologics (marketed / under development) are suited for delivery via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. These biologics (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems. We believe that some of these drugs, if tested and approved with large volume wearable injectors, are likely to make a substantial contribution to the market’s evolution in the mid-long term.

5. Innovation in the field is primarily being driven by start-ups / small companies; examples of firms working for delivery of non-insulin biologics include (in alphabetical order) Elcam Drug Delivery Systems, Enable Injections, NeuroDerm, scPharmaceuticals, Sensile Medical. Notable examples of start-ups that have taken initiatives for delivery of insulin include Cellnovo, CeQur, Debiotech, PicoSulin, SOOIL and ViCentra. In addition, a number of large companies are making notable contribution in this field; prominent players include Becton Dickinson, Johnson & Johnson, Medtronic, Roche and West Pharmaceutical Services.

6. Several other companies engaged in this domain have reported positive clinical outcomes of their drug-device combinations. scPharmaceuticals is expecting the commercial launch of its two product candidates for the drugs furosemide and cephalosporin in 2017 / 18. In addition, Neuroderm and SteadyMed Therapeutics are also hopeful of making their products commercially available in the near future. At the same time, insulin delivery devices, such as OmniPod, are now also being explored for the delivery of non-insulin drugs, such as the gonadotropin-releasing hormone developed by Ferring Pharmaceuticals.

7. The overall market for large volume wearable injectors is likely to grow at an aggressive rate of over 150%. We believe that OmniPod will continue to lead the market for insulin delivery. However, majority of the growth is likely to come from drug-device combinations under trials for non-insulin biologics. In our base scenario, we have predicted that the annual sales volume of such devices could be over 40 million units by 2027.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the large volume wearable injectors market.

Chapter 3 provides a general introduction to the market and highlights the growing demand for self-administration injection devices. The chapter lays emphasis on the need for such devices driven by the rising incidence of chronic diseases and emergency cases reported per day. Subsequently, it covers the different types of self-injection devices available in the market, highlighting their advantages. This section also features a brief discussion on the concerns related to needlestick injuries and emphasizes the growing preference for safe and easy-to-use devices.

Chapter 4 presents two separate lists of the large volume wearable injectors for insulin and the other biologics. In addition, the chapter includes a detailed analysis of both these lists based on the products’ status of development, device category (infusion pump / patch pump), type of dose (bolus / continuous) and the capacity of each device. Specifically for insulin delivery devices, we have identified whether the device is equipped with continuous glucose monitoring (CGM) monitoring or not.

Chapter 5 presents key takeaways from the market landscape of this emerging field. It features a comparison of product competitiveness and supplier power of each device in the form of a 2 x 2 matrix. In addition, the chapter includes a grid based representation of devices based on the target indication, status of development, type of dose (continuous / bolus / both) and type of device (patch pump / infusion pump). The chapter also provides an analysis of the patents granted / filed in this space over the last three years.

Chapter 6 presents detailed profiles on the large volume wearable injectors being developed for biologics / drugs other than insulin. The profiles include information about the developer of the device, device specifications and features, advantages, current status of development and related collaborations. We have presented such insights on 10 devices capable of delivering large dosage volumes.

Chapter 7 is focused on the devices developed / being developed for the administration of insulin. It presents information on diabetes, the most popular target indication, including information on its epidemiology and the evolution of insulin-delivery systems. Additionally, it includes detailed profiles on some of the large volume wearable devices developed / being developed for the delivery of insulin. Each profile covers information on the device developer, device specifications, advantages and the associated developments. The chapter also includes a social media analysis highlighting the popularity of these devices in the industry.

Chapter 8 provides detailed case studies on the drugs / therapies that are currently being evaluated with the devices mentioned in chapter 4. Each case study includes drug / therapy specifications, respective mechanisms of action, current status of development, information on the sales of each product, dosage and recent developments.

Chapter 9 presents a list of candidates (marketed / pipeline) that have the potential to be administered using large volume wearable injectors in the future. The likelihood of delivery of a molecule was estimated based on the volume of dose, mode of administration, frequency of administration, standard / weight-based dose and the chronicity of the target indication.

Chapter 10 provides projections of the future opportunity of the large volume wearable injectors market for biologics till 2027. It highlights the market size of such injectors (in terms of value) and the number of units that are likely to be sold within the forecast time period. We have clearly laid out the forecast methodology along with the key assumptions that were taken into consideration for estimating the market size.

Chapter 11 includes comprehensive profiles of the key companies that are active in this market. We have profiled companies (presented in an alphabetical order) developing devices for administration of insulin / other biologics. Each company profile includes a company overview, details on its financial performance, product portfolio and collaborations.

Chapter 12 provides a SWOT analysis, highlighting strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 13 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of large volume wearable injectors market based on the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 16 is an appendix, which provides a list of companies and organizations mentioned in this report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report:
1. 5AM Ventures
2. Abbott Laboratories
3. AbbVie
4. AbGenomics
5. Ablynx
6. Acceleron Pharma
7. Accord Healthcare
8. Aduro Biotech
9. Advaxis
10. Agenus
11. AgonOx
12. Akorn
13. Alder BioPharmaceuticals
14. Alexion Pharmaceuticals
15. Alixinox Pharmaceuticals
16. Alnylam Pharmaceuticals
17. AlphaCore Pharma
18. Altor BioScience
19. Alzheimer’s Association
20. American Academy of Neurology
21. American Nurses Association
22. Amgen
23. Amphastar Pharmaceuticals
24. Animas Corporation
25. Antares Pharma
26. Antigen Express
27. Apotex
28. Arbutus Biopharma
29. Argos Therapeutics
30. Arteaus Therapeutics
31. Arthurian Life Sciences
32. ARTORG Center for Biomedical Research
33. Asante Solutions
34. Aspen Pharmacare
35. Astellas Pharma
36. Asthma and Allergy Foundation of America
37. AstraZeneca
38. Athersys
39. Aurum Pharmaceuticals
40. AVEO Oncology
41. Banque
42. Bardy Diagnostics
43. Baxter
44. Bayer
45. Bayhill Therapeutics
46. Becton Dickinson
47. Bespak
48. Bigfoot Biomedical
49. BioArctic Neuroscience
50. bioCSL
51. Biogen
52. BioInvent International
53. Bioject Medical Technologies
54. BioMarin Pharmaceutical
55. Bio-Path Holdings
56. Biotest
57. Boehringer Ingelheim
58. Bristol-Myers Squibb
59. Cala Health
60. Calando Pharmaceuticals
61. Cam Med
62. Canadian Institute for Health Information
63. Canadian Intellectual Property Office
64. Cancer Advances
65. CANÈ
66. Cardiome Pharma
67. Catalyst Biosciences
68. Celgene
69. Celldex Therapeutics
70. Cellerant Therapeutics
71. Cellnovo
72. CEL-SCI Corporation
73. Centers for Disease Control and Prevention
74. CeQur
75. Chugai Pharmaceutical
76. Cincinnati Children’s Hospital Medical Center
77. Cipla
78. Circadian Technologies
79. Cleveland BioLabs
80. CONNECT
81. Consort Medical
82. Crealta Pharmaceuticals
83. CROSSJECT
84. CSL Behring
85. CureTech
86. CytoDyn
87. Cytonet
88. Daikyo Seiko
89. Debiotech
90. Deerfield Management Company
91. DEKA
92. Dekkun
93. Denderon
94. Dexcom
95. Diamyd Medical
96. Diasend
97. Bern University Hospital
98. Duke University Medical Center
99. Egalet Corporation
100. Eisai
101. Elan Pharmaceuticals
102. Elcam Drug Delivery Devices
103. Eli Lilly
104. Elias Group
105. Elusys Therapeutics
106. Emcure Pharmaceuticals
107. EMD Serono
108. Emergent BioSolutions
109. Emory University Hospital
110. Enable Injections
111. Endeavour Vision
112. Endo Pharmaceuticals
113. Endocyte
114. Eternity Healthcare
115. European Agency of Occupational Safety and Health
116. European Pharma Group
117. Federated Investors
118. Ferring Pharmaceuticals
119. FibroGen
120. Finox Biotech
121. Five Prime Therapeutics
122. Flex (formerly Flextronix)
123. Flowonix Medical
124. Forma Medical Device Design
125. Fresenius Kabi
126. Galaxy Biotech
127. Galena Biopharma
128. Genentech
129. Generon Corporation (Shanghai)
130. Geno Pharmaceuticals
131. Genzyme Corporation
132. Gilead Sciences
133. Gland Pharma
134. GlaxoSmithKline
135. Gliknik
136. Glooko
137. Halozyme Therapeutics
138. HanAll BioPharma
139. Hanmi Pharmaceutical
140. HealthPrize Technologies
141. Heart Failure Clinical Research Network
142. Heart Failure Society of America
143. Hemispherx Biopharma
144. Hospira
145. ImClone Systems
146. Immatics Biotechnologies
147. Immune Response BioPharma
148. Immunocore
149. ImmunoFrontier
150. ImmunoGen
151. Immunomedics
152. Immunotope
153. Immunovaccine
154. Immunovative Therapies
155. Ind-Swift
156. Ingenus Pharmaceuticals
157. INJEX Pharma
158. Inovio Pharmaceuticals
159. Insulet Corporation
160. Insuline Medical
161. International Diabetes Federation
162. Ionis Pharmaceuticals
163. IP Holdings
164. Ipca Laboratories
165. Ipsen
166. iSense CGM
167. Janssen Biotech
168. Johnson & Johnson
169. Kaléo
170. KaloBios Pharmaceuticals
171. KB Partners
172. Kyowa Hakko Kirin
173. Leading Pharma
174. LifeScan
175. Lundbeckfonden Ventures
176. MabVax Therapeutics
177. MacroGenics
178. Massachusetts General Hospital
179. Mayo Clinic
180. MEDAXOR
181. Medical International Technology
182. Medicom Innovation Partner
183. Medicus Engineering
184. MedImmune
185. Medimop Medical Projects
186. Medipacs
187. Medtronic
188. Medtrum
189. MENTRIK Biotech
190. Merck
191. Meridian Medical Technologies
192. Merrimack Pharmaceuticals
193. Merz Pharma
194. MetroHealth System
195. Mode AGC
196. Modi Mundi Pharma
197. MolMed
198. MorphoSys
199. Morphotek
200. Mylan
201. Bar Ilan University
202. National Institute for Clinical Excellence
203. National Institutes of Health
204. Neogenix Oncology
205. Neon Laboratories
206. NeuroDerm
207. Noble
208. Norwich Pharmaceuticals
209. Novartis
210. Novo Nordisk
211. Nuron Biotech
212. Occupational Safety and Health Administration
213. Octapharma
214. Omeros
215. OncoGenex Pharmaceuticals
216. OncoMed Pharmaceuticals
217. OncoPep
218. Optimer Pharmaceuticals
219. OrbiMed
220. ORI Healthcare Fund
221. Otsuka Pharmaceutical
222. Owen Mumford
223. Peregrine Pharmaceuticals
224. Perqflo
225. Pfizer
226. PharmaJet
227. PhaseBio Pharmaceuticals
228. Pico Life Technologies
229. PicoSulin
230. Pique Therapeutics
231. Pliva
232. Pluristem Therapeutics
233. Polaris Pharmaceuticals
234. Polynoma
235. Portola Pharmaceuticals
236. Prachi Pharmaceuticals
237. Progenics Pharmaceuticals
238. Promethera Biosciences
239. Prometheus Laboratories
240. Protalix BioTherapeutics
241. Qualitest Pharmaceuticals
242. Quest Pharmatech
243. Quintessence Biosciences
244. RAD BioMed
245. Ranbaxy Laboratories
246. Ratio Drug Delivery
247. Regeneron Pharmaceuticals
248. rEVO Biologics
249. Roche
250. Roehr Products
251. Roxane Laboratories
252. Sagent Pharmaceuticals
253. Salix Pharmaceuticals
254. Samson Ventures Partners
255. Sandoz
256. Sangamo BioSciences
257. Sanofi
258. Sarpeta Therapeutics
259. SBIR Healthcare
260. Schroders
261. SciGen
262. scPharmaceuticals
263. Seattle Genetics
264. Sensile Medical
265. Shionogi
266. Shire
267. Sigma-Tau Pharmaceuticals
268. SillaJen BioTherapeutics
269. SOOIL
270. SteadyMed Therapeutics
271. Stemline Therapeutics
272. STMicroelectronics
273. Sun Pharmaceutical Industries
274. Sunovion Pharmaceuticals
275. Syntax Corporation
276. TaiMed Biologics
277. Takeda Pharmaceutical Company
278. Tamir Biotechnology
279. Tandem Diabetes Care
280. Teva Pharmaceutical Industries
281. TG Therapeutics
282. The Tech Group
283. Tidepool
284. Touche Medical
285. TRACON Pharmaceuticals
286. TypeZero Technologies
287. UCB
288. Unilife Corporation
289. United Biomedical
290. United States Patent and Trademark Office
291. United Therapeutics
292. University of Bern
293. US WorldMeds
294. Vaccinex
295. Vaccinogen
296. Valeritas
297. Valtronic
298. VBL Therapeutics
299. VI Partners
300. ViCentra
301. Vintage Pharmaceuticals
302. West Pharmaceutical Services
303. Wockhardt
304. Woodford Investment Management
305. World Intellectual Property Organization
306. XBiotech
307. Xencor
308. XOMA Corporation
309. YOFimeter
310. Ypsomed


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Devices
3.3. Self-Administration: An Emerging Trend
3.3.1. Rising Burden of Chronic Diseases
3.3.2. Need for Immediate Treatment in Emergency Situations
3.3.3. Expansion of Injectable Biologics Pipeline
3.3.4. Systems Available for Self-administration
3.3.4.1. Prefilled Syringes
3.3.4.2. Pen-Injectors
3.3.4.3. Autoinjectors
3.3.4.4. Needle-Free Injectors
3.3.4.5. Large Volume Wearable Injectors
3.3.5. Needlestick Injuries
3.3.5.1. Incidence and Cost Burden
3.3.5.2. Prevention of Needlestick Injuries
3.3.5.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Advantages and Future Prospects of Self-Injection Systems
4. LARGE VOLUME WEARABLE INJECTORS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Development Landscape
4.3. Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
.3.1. Distribution by Stage of Development
4.3.2. Distribution by Storage Capacity
4.3.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
4.3.4. Distribution by Type of Dose (Bolus / Continuous)
4.3.5. Distribution by Usability (Disposable / Reusable)
4.3.6. Distribution by Leading Players
4.4. Large Volume Wearable Injectors: Development Landscape for Insulin
4.4.1. Distribution by Stage of Development
4.4.2. Distribution by Device Volume
4.4.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
4.4.4. Distribution by Usability (Disposable / Reusable)
4.4.5. Distribution by Availability of CGM System
4.4.6. Distribution by Leading Players
4.5. Large Volume Wearable Injectors: Distribution by Geography
5. PRODUCT COMPETITIVENESS, CLINICAL DESIGN AND PATENT ANALYSIS
5.1. Chapter Overview
5.2. Product Competitiveness Analysis
5.2.1. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
5.2.2. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
5.3. Grid Analysis: Distribution of Large Volume Wearable Injectors Based on Development Phase and Type of Dosage
5.4. Patent Analysis: Large Volume Wearable Injectors, 2013-2016
5.4.1. Distribution by Current Status
5.4.2. Distribution by Year
5.4.3. Distribution by Key Players
5.4.4. Distribution by Regional Approving Authorities
5.4.5. Distribution by the Type of Patent
5.4.6. Distribution by Patent Expiry Year
6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN BIOLOGICS: DEVICE PROFILES
6.1. Chapter Overview
6.2. eLVD Patch Pump (Elcam Drug Delivery Devices (E3D))
6.2.1. Introduction
6.2.2. Product Description
6.2.3. Advantages
6.3. Enable Injector (Enable Injections)
6.3.1. Introduction
6.3.2. Product Description
6.3.3. Usage
6.3.4. Advantages
6.3.5. Recent Developments
6.4. Lapas® (Bespak)
6.4.1. Introduction
6.4.2. Product Description
6.4.3. Advantages
6.5. BD Libertas™ Wearable Injector (Becton Dickinson)
6.5.1. Introduction
6.5.2. Product Description
6.5.3. Usage
6.5.4. Advantages
6.6. PatchPump® (SteadyMed Therapeutics)
6.6.1. Introduction
6.6.2. Product Description
6.6.3. Usage
6.6.4. Advantages
6.6.5. Recent Developments
6.7. Precision-Therapy™ Wearable Injector, Flex-Therapy™ Wearable Injector and Flex-Therapy™ Mini Wearable Injector (Unilife Corporation)
6.7.1. Introduction
6.7.2. Product Description
6.7.3. Usage
6.7.4. Advantages
6.7.5. Recent Developments
6.8. sc2™Wear Infusor (scPharmaceuticals)
6.8.1. Introduction
6.8.2. Product Description
6.8.3. Advantages
6.8.4. Recent Developments
6.9. Single-use Injection Device (Roche)
6.9.1. Introduction
6.9.2. Product Description
6.9.3. Usage
6.9.4. Advantages
6.9.5. Recent Developments
6.10. SenseBolus, SensePatch and SenseTrial (Sensile Medical)
6.10.1. Introduction
6.10.2. Product Description
6.10.3. Usage
6.10.4. Advantages
6.10.5. Recent Developments
6.11. SmartDose® Electronic Wearable Injector (West Pharmaceutical Services)
6.11.1. Introduction
6.11.2. Product Description
6.11.3. Usage
6.11.4. Advantages
6.11.5. Recent Developments
7. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN: DEVICE PROFILES
7.1. Chapter Overview
7.2. Diabetes: An Introduction
7.2.1. Epidemiology
7.2.2. Available Therapies
7.2.3. Need for Diabetes Management Systems
7.3. Advanced Insulin Delivery Systems: Device Profiles
7.3.1. ACCU-CHEK® (Roche Diagnostics)
7.3.1.1. Introduction
7.3.1.2. Product Information
7.3.1.3. Advantages
7.3.1.4. Recent Developments
7.3.2. DANA Diabecare® Insulin Pumps (SOOIL)
7.3.2.1. Introduction
7.3.2.2. Product Information
7.3.2.3. Advantages
7.3.3. JewelPUMP™ I and JewelPUMP™ II (Debiotech)
7.3.3.1. Introduction
7.3.3.2. Product Information
7.3.3.3. Advantages
7.3.3.4. Recent Developments
7.3.4. MiniMed® 530G (Medtronic)
7.3.4.1. Introduction
7.3.4.2. Product Information
7.3.4.3. Advantages
7.3.4.4. Recent Developments
7.3.5. mylife™ YpsoPump® (Ypsomed)
7.3.5.1. Introduction
7.3.5.2. Product Information
7.3.5.3. Advantages
7.3.6. OmniPod® (Insulet Corporation)
7.3.6.1. Introduction
7.3.6.2. Product Information
7.3.6.3. Advantages
7.3.6.4. Recent Developments
7.3.7. OneTouch Via™ (Johnson & Johnson)
7.3.7.1. Introduction
7.3.7.2. Product Information
7.3.7.3. Usage
7.3.7.4. Advantages
7.3.8. PAQ™ (CeQur)
7.3.8.1. Introduction
7.3.8.2. Product Information
7.3.8.3. Usage
7.3.8.4. Advantages
7.3.8.5. Recent Developments
7.3.9. t:flex® (Tandem Diabetes Care)
7.3.9.1. Introduction
7.3.9.2. Product Information
7.3.9.3. Advantages
7.3.9.4. Recent Developments
7.4. Large Volume Wearable Injectors for Insulin: Trends on Social Media
7.4.1. Large Volume Wearable Injectors for Insulin: Twitter Trends
7.4.2. Large Volume Wearable Injectors for Insulin: Device Recalls
7.4.3. Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring
8. CASE STUDIES: DRUG-DEVICE COMBINATIONS UNDER EVALUATION
8.1. Chapter Overview
8.2. Repatha® / Evolocumab / AMG 145
8.2.1. Drug Specifications
8.2.2. Mechanism of Action
8.2.3. Development History
8.2.4. Current Status of Development
8.2.5. Dosage and Sales Information
8.3. Treprostinil
8.3.1. Drug Specifications
8.3.2. Mechanism of Action
8.3.3. Development History
8.3.4. Current Status of Development
8.3.5. Dosage and Sales Information
8.4. Furosemide
8.4.1. Drug Specifications
8.4.2. Mechanism of Action
8.4.3. Development History
8.4.4. Current Status of Development
8.4.5. Dosage and Sales Information
8.5. Herceptin®
8.5.1. Drug Specifications
8.5.2. Mechanism of Action
8.5.3. Development History
8.5.4. Current Status of Development
8.5.5. Dosage and Sales Information
8.6. ND0612 / Levadopa and Carbidopa
8.6.1. Drug Specifications
8.6.2. Mechanism of Action
8.6.3. Development History
8.6.4. Current Status of Development
8.6.5. Dosage and Sales Information
8.7. ND0701 / Apomorphine
8.7.1. Drug Specifications
8.7.2. Mechanism of Action
8.7.3. Current Status of Development
8.7.4. Dosage and Sales Information
8.8. SMT-201 / Ketorolac
8.8.1. Drug Specifications
8.8.2. Mechanism of Action
8.8.3. Development History
8.8.4. Current Status of Development
8.8.5. Dosage and Sales Information
8.9. Ceftriaxone
8.9.1. Drug Specifications
8.9.2. Mechanism of Action
8.9.3. Development History
8.9.4. Current Status of Development
8.9.5. Dosage and Sales Information
9. TARGET BIOLOGICS FOR LARGE VOLUME WEARABLE INJECTORS
9.1. Chapter Overview
9.2. Marketed Biologics
9.2.1. Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
9.2.2. Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
9.2.3. Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
9.3. Pipeline Molecules
9.3.1. Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
9.3.2. Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
9.3.3. Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Key Assumptions
10.4. Forecast Output
10.4.1. Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2017-2027
10.4.2. Large Volume Wearable Injectors Market for Insulin, 2017-2027
11. LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS
11.1. Chapter Overview
11.2. Becton Dickinson
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Product Portfolio
11.2.4. Collaborations
11.2.5. Future Outlook
11.3. CeQur
11.3.1. Company Overview
11.3.2. Product Portfolio
11.3.3. Future Outlook
11.4. Debiotech
11.4.1. Company Overview
11.4.2. Product Portfolio
11.4.3. Collaborations
11.4.4. Future Outlook
11.5. Insulet Corporation
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Product Portfolio
11.5.4. Collaborations
11.5.5. Future Outlook
11.6. Roche Laboratories
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Product Portfolio
11.6.4. Collaborations
11.6.5. Future Outlook
11.7. Sensile Medical
11.7.1. Company Overview
11.7.2. Product Portfolio
11.7.3. Collaborations
11.7.4. Future Outlook
11.8. SteadyMed Therapeutics
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Product Portfolio
11.8.4. Collaborations
11.8.5. Future Outlook
11.9. Tandem Diabetes Care
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Product Portfolio
11.9.4. Collaborations
11.9.5. Future Outlook
11.10. Unilife Corporation
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Product Portfolio
11.10.4. Collaborations
11.10.5. Future Outlook
11.11. West Pharmaceutical Services
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Product Portfolio
11.11.4. Collaborations
11.11.5. Future Outlook
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
13. CONCLUSION
13.1. Novel Drug / Therapy Delivery Solutions Offer a number of Advantages, including Self-Administration in the Home-care Setting
13.2. Technical Improvements have Led to the Development of Advanced Large Volume Wearable Delivery Systems Having Multiple Useful Features
13.3. The Market, Characterized by the Presence of both Large and Small Companies, is Likely to be Impacted by the Growth of the Biologics Market
13.4. Partnerships and Venture Capital Financing have Emerged as Key Drivers of Growth in this Upcoming Area
13.5. The Large Volume Wearable Injector Market is Projected to Grow at an Aggressive Pace Over the Next Decade
13.6. Concluding Remarks
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Menachem Zucker, VP and Chief Scientist, Elcam Medical
14.3. Michael Hooven, CEO, Enable Injections
14.4. Ben Moga, President, Ratio Drug Delivery
14.5. Pieter Muntendam, President and CEO, scPharmaceuticals
14.6. Graham Reynolds, VP & GM, Global Biologics and Tiffany H. Burke, Director, Global Communications, West Pharmaceutical Services
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Types of Drug Delivery Systems
Figure 3.2 Types of Self-Injection Devices
Figure 3.3 Worldwide Evolution in Healthcare Safety Legislation
Figure 4.1 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Figure 4.2 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Figure 4.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Figure 4.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
Figure 4.5 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
Figure 4.6 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
Figure 4.7 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Figure 4.8 Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
Figure 4.9 Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Figure 4.10 Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
Figure 4.11 Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Figure 4.12 Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
Figure 4.13 Large Volume Wearable Injectors: Distribution by Geography
Figure 4.14 Large Volume Wearable Injectors: Regional Landscape
Figure 5.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
Figure 5.2 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
Figure 5.3 Grid Analysis: Distribution by Stage of Development and Type of Dosage
Figure 5.4 Patent Analysis: Distribution by Current Status
Figure 5.5 Patent Analysis: Distribution by Year
Figure 5.6 Patent Analysis: Distribution by Key Players
Figure 5.7 Patent Analysis: Distribution by Regional Approving Authorities
Figure 5.8 Patent Analysis: Distribution by the Type of Patent
Figure 5.9 Patent Analysis: Distribution by Patent Expiry Year
Figure 7.1 Diabetes: Worldwide Distribution of the Patients (2015)
Figure 7.2 Prevalence of Diabetes: Distribution by Continent (In Million)
Figure 7.3 Insulin-Based Therapies for Diabetes
Figure 7.4 Non-Insulin Therapies for Diabetes
Figure 7.5 Large Volume Wearable Injectors for Insulin: Twitter Trends (2010-2015)
Figure 7.6 Large Volume Wearable Injectors for Insulin: Twitter Word Cloud (2010-2015)
Figure 7.7 Large Volume Wearable Injectors for Insulin: Device Recalls (2010-2015)
Figure 7.8 Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring
Figure 8.1 Treprostinil IV Formulation: Annual Sales 2012 - Q1-Q3 2016 (USD Million)
Figure 8.2 Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
Figure 8.3 Herceptin®: Annual Sales, 1999-2015 (CHF Million)
Figure 8.4 Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
Figure 8.5 Apokyn®: Annual Sales, 2011-2015 (USD Million)
Figure 8.6 Rocephin®: Annual Sales, 2014-2015 (CHF Million)
Figure 9.1 Marketed / Under Development Molecules: Parameters and Scoring Criteria
Figure 10.1 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
Figure 10.2 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
Figure 10.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
Figure 10.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
Figure 10.5 Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
Figure 10.6 Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
Figure 11.1 Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
Figure 11.2 Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
Figure 11.3 Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
Figure 11.4 Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
Figure 11.5 Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million)
Figure 11.6 Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
Figure 11.7 West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
Figure 13.1 Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)
LIST OF TABLES
Table 3.1 List of Prefilled Syringes
Table 3.2 List of Pen-Injector Systems
Table 3.3 List of Autoinjector Systems
Table 3.4 List of Needle-Free Injectors
Table 4.1 Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
Table 4.2 Large Volume Wearable Injectors: Development Landscape for Insulin
Table 6.1 Large Volume Wearable Injectors for Non-Insulin Biologics: List of Devices Profiles
Table 7.1 Advanced Insulin Delivery Systems
Table 7.2 DANA Diabecare®: Specifications
Table 7.3 JewelPUMP™: Specifications
Table 7.4 JewelPUMP™: Advantages
Table 7.5 MiniMed® 530G: Specifications
Table 7.6 mylife™ YpsoPump®: Specifications
Table 7.7 OmniPod®: Specifications
Table 7.8 t:flex®: Specifications
Table 8.1 Large Volume Wearable Injectors: Drugs under Evaluation
Table 8.2 Repatha®: Clinical Trials
Table 8.3 Remodulin®: Dosage Regimen
Table 8.4 Orenitram®: Dosage
Table 8.5 Tyvaso®: Dosage
Table 8.6 Furosemide: Clinical Trials
Table 8.7 Furosemide: Manufacturers and Suppliers
Table 8.8 Subcutaneous Herceptin®: Clinical Trials
Table 8.9 ND0612: Clinical Trials
Table 8.10 ND0612H: Phase II Trials (Objectives and Results)
Table 8.11 Levodopa / Carbidopa: Manufacturer and Suppliers
Table 8.12 Ketorolac Tromethamine: Manufacturers and Suppliers
Table 9.1 Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.2 Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.3 Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.4 Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.5 Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
Table 9.6 Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors
Table 10.1 Large Volume Wearable Injectors for Non-Insulin Biologics (Approved / Under Development)
Table 11.1 Large Volume Wearable Injectors: Key Players
Table 11.2 Becton Dickinson: Medical Devices Portfolio
Table 11.3 Debiotech: Medical Devices Portfolio
Table 11.4 Sensile Medical: Medical Devices Portfolio
Table 11.5 SteadyMed Therapeutics: Medical Devices Portfolio
Table 11.6 t:slim X2™ Insulin Pump: Features
Table 11.7 t:slim X2™ Insulin Pump: Technical Specifications
Table 11.8 t:flex® Insulin Pump: Features
Table 11.9 t:flex® Insulin Pump: Technical Specifications
Table 11.10 West Pharmaceutical Services: Medical Devices Portfolio
Table 12.1 Large Volume Wearable Injectors: SWOT Analysis
Table 12.2 Recall of Device (Autoinjectors and Prefilled Syringes)
Table 15.1 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Table 15.2 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Table 15.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Table 15.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
Table 15.5 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
Table 15.6 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
Table 15.7 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Table 15.8 Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
Table 15.9 Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
Table 15.10 Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
Table 15.11 Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Table 15.12 Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
Table 15.13 Large Volume Wearable Injectors: Distribution by Geography
Table 15.14 List of Patents, 2013-2016
Table 15.15 Patent Analysis: Distribution by Current Status
Table 15.16 Patent Analysis: Distribution by Year
Table 15.17 Patent Analysis: Distribution by Key Players
Table 15.18 Patent Analysis: Distribution by Regional Approving Authorities
Table 15.19 Patent Analysis: Distribution by the Type of Patent
Table 15.20 Patent Analysis: Distribution by Patent Expiry Year
Table 15.21 Diabetes: Worldwide Distribution of the Patients (2015)
Table 15.22 Prevalence of Diabetes: Distribution by Continent (In Million)
Table 15.23 Treprostinil IV Formulation: Annual Sales, 2012 - Q1-Q3 2016 (USD Million)
Table 15.24 Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
Table 15.25 Herceptin®: Annual Sales, 1999-2015 (CHF Million)
Table 15.26 Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
Table 15.27 Apokyn®: Annual Sales, 2011-2015 (USD Million)
Table 15.28 Rocephin®: Annual Sales, 2014-2015 (CHF Million)
Table 15.29 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
Table 15.30 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, 2017-2027 (USD Million)
Table 15.31 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, 2017-2027 (USD Million)
Table 15.32 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
Table 15.33 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, Number of Units, 2017-2027 (Million)
Table 15.34 Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, Number of Units, 2017-2027 (Million)
Table 15.35 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
Table 15.36 Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
Table 15.37 Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
Table 15.38 Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
Table 15.39 Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
Table 15.40 Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
Table 15.41 Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
Table 15.42 Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
Table 15.43 Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million)
Table 15.44 Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
Table 15.45 West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
Table 15.46 Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report